Carl L. Gordon - 12 Sep 2024 Form 4 Insider Report for MBX Biosciences, Inc. (MBX)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: MBX
Reported as of: 12 Sep 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Sep 2024, 17:19:29 UTC
Prior SEC filing: 23 Aug 2024
Next SEC filing: 17 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Richard Bartram, attorney-in-fact

Key filing fact

Carl L. Gordon filed Form 4 for MBX Biosciences, Inc. (MBX) on 13 Sep 2024.

Key facts

This page summarizes Carl L. Gordon's Form 4 filing for MBX Biosciences, Inc. (MBX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Sep 2024, 17:19.

Change

Previous filing in this sequence was filed on 23 Aug 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MBX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +15,963
Change %
Price: $0.000000
Shares after: 15,963
Date: 12 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,963
Exercise price: $16.00
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Footnote F2

Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.